Hepatitis C Therapy
ViroPharma, Wyeth initiate dosing in phase 2 study of drug for treating hepatitis C patients
Published in Hepatitis Weekly, November 20th, 2006
The phase 2 study is being conducted with Wyeth Pharmaceuticals, a division of Wyeth (WYE), ViroPharma's partner in development of HCV-796.
The objectives of this trial are to assess the safety, tolerability, pharmacokinetic profile, and antiviral activity of HCV-796, when used in combination with pegylated interferon alfa-2b plus ribavirin compared to the current standard of care in treatment-naive subjects with HCV...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-11-20)
More Articles from Hepatitis Weekly
- Hepatitis C Research
Patients who recover from hepatitis C have lower risk of reinfection - Hepatitis C Therapy
Study shows new drug combo is effective in Hepatitis C nonresponders - Anemia Risk Factors
Researchers at Chang-Gung University, Department of Internal Medicine target anemia risk factors - Hepatitis B Virus Epidemiology
Researchers at Institute of Public Health target hepatitis b virus epidemiology - Hepatitis B Virus Therapy
New hepatitis b virus therapy research from Weizmann Institute of Science, Department of Molecular Genetics discussed - Hepatitis B Virus Therapy
Scientists at Hiroshima University, Division of Frontier Medical Science target hepatitis b virus therapy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
